Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Johnson & Johnson - Driving EGFR-mutant NSCLC care forward

Breaking barriers upon EGFR treatment resistance

Date

15 Sep 2024

Session

Johnson & Johnson - Driving EGFR-mutant NSCLC care forward

Topics

Cancer Biology;  Pathology/Molecular Biology;  Targeted Therapy;  Cancer Epidemiology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Sanjay Popat

Authors

S. Popat

Author affiliations

  • Department Of Medicine, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.